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resumo 
 
 
As microagulhas (MN) são microcomponentes inovadores na entrega de 
fármacos via transdérmica de forma quase impercetível para o paciente. De 
metais a polímeros, as MN têm sido fabricadas com uma grande variedade de 
materiais, embora com algumas restrições quanto à resistência mecânica 
(limitações relacionadas com a perfuração da pele), armazenamento e altos 
custos de fabrico. 
Na presente tese, foram utilizados cimentos à base de fosfato tricálcico (TCP) 
para o fabrico de MN brushíticas e apatíticas via micromoldagem. Foram 
sintetizados dois pós, -TCP e BTCP (bifásico, -TCP + -TCP). Partindo 
destes pós, foram preparadas pastas cimentícias na ausência e na presença de 
fármaco, variando a razão líquido/pó e caracterizadas em termos de tempos de 
presa inicial e final, parâmetros importantes para o enchimento e desmoldagem 
dos componentes. Os cimentos resultantes foram caracterizados em termos de 
porosidade, fases cristalinas, resistência mecânica, microestrutura da superfície 
e metodologia de secagem. As formulações de cimento que apresentaram os 
resultados mais promissores para o fabrico de MN foram utilizadas para estudar 
a taxa de libertação do fármaco. Uma solução aquosa de ácido cítrico com 
concentração adequada como líquido de presa revelou ser a mais adequada. O 
antibiótico levofloxacina (LEV) foi utilizado como fármaco modelo.  
Os resultados obtidos mostraram que a adição de LEV aumenta os tempos de 
presa iniciais e finais das pastas cimentícias e diminui as propriedades 
mecânicas dos cimentos. Uma libertação de fármaco de 100% foi alcançada 
para todas as formulações de cimento testadas após 48 horas de imersão. Do 
estudo cinético da libertação de fármaco verificou-se que o "Coupled 
Mechanism" foi o que melhor descreveu o mecanismo de libertação da LEV em 
todas as formulações de cimentos testadas. Com as pastas cimentícias foi 
possível obter microagulhas afiadas por enchimento de micromoldes e 
devidamente desmoldadas. Através da avaliação da sua resistência mecânica é 
possível prever que as MN obtidas apresentam estrutura e propriedades 
mecânicas adequadas para a perfuração da pele, uma vez que, é conhecido da 
literatura que a força necessária para que as agulhas perfurarem a pele humana 
é à volta de 1-5 N. Das várias agulhas testadas, os valores da força necessária 
para quebrar a ponta situam-se num intervalo de 57 a 110 N.  
As MN à base de cimentos de TCP apresentam características adequadas para 
serem utilizadas como meio de administração de fármacos via transdérmica com 
futuro em diversas aplicações médicas. O processo de produção utilizado traz 
imensas vantagens quando comparado com os métodos atuais para a produção 
de microcomponentes, sendo simples, económico e replicável. 

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
keywords 
 
Microneedles, calcium phosphate cements, controlled drug release, α-TCP, β-
TCP, Levofloxacin 
 
abstract 
 
Microneedles (MN) are an up and coming technology offering almost 
inconspicuous transdermal drug delivery system. From metals to polymers, 
microneedles have been fabricated with a high variety of materials, although with 
some constraints regarding mechanical strength (limitations related to skin 
perforation), storage and high manufacturing costs.  
In the present thesis, self-setting bioceramics were used to fabricate brushitic
and apatitic MN by micro-molding casting. Two precursor powders were 
synthesized to obtain -TCP and BTCP (biphasic,-TCP+-TCP) as main 
phases. Cement pastes were prepared in absence and in presence of drug, 
varying liquid to powder ratio and characterized in terms of initial and final setting 
times, important parameters for casting and de-molding procedures. The
resulting cements were characterized for their porosity, crystalline phases, 
mechanical strength, surface morphology and drying methodology. The cement 
formulations that presented the most promising results for MN fabrication
(flowability during casting and adequate mechanical properties for de-molding 
without damage) were used to study drug release rate. A citric acid solution with 
adequate concentration was the most suitable as setting liquid in both MN types. 
The antibiotic levofloxacin was used as a model drug.  
The results show that the addition of levofloxacin increases the setting times of 
the cement pastes and decreases the mechanical properties of the cements. A 
100% drug release was achieved for all the tested cement formulations after 48
hours of immersion time. The drug release kinetics were evaluated being 
determined that the "coupled mechanism" is the one that best described the 
release mechanism of cements obtained from both powders. Sharp MN were 
successfully casted and de-molded. MN tip obtained in this work present 
adequate mechanical properties for skin perforation without breakage, since 
according to literature the insertion forces necessary for perforate human skin is
around 1-5 N. Among all tested MN, the force necessary to break the tip is in the 
range 57 to 110 N.   
From the evaluated work, calcium phosphate cement based MN present 
adequate characteristics to be used as a promising drug delivery
microcomponent for biomedical applications. The fabrication process used 
(micromolding) has several advantages when compared to the current 
production MN processes being simple, cost-effective and replicable.  
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Ever since man discovered ways to treat illness in its many forms. The way how such 
treatments are applied is of major importance and directly affects the body’s response, 
either positively or negatively. As so, the interest in discovering new ways to deliver 
chemicals as grown alongside the advances in drug discovery. The effectiveness of a drug 
and how it behaves in the body is directly related to the way it is delivered. 
Traditionally, medicines (meaning drugs) are delivered to the body via one of  two 
major forms: orally, with pills and syrups, and directly in the bloodstream, via 
hypodermic needles [1]. When using the oral method, drugs must pass through the 
digestive system, which can lead to a change in the drug’s composition (or even loss) due 
to the gastric juices and metabolization by the liver [2]. During the delivery and diffusion 
process drug integrity must be guaranteed, as well as, it side effects that can affect the 
digestive system and it behavior in such environment [2]. 
The use of hypodermic needles (being subcutaneous, intravenous, intramuscular 
or intradermal) eliminate such problems, bypassing completely the digestive system, 
delivering the drug directly to the bloodstream. When choosing this delivery method 
several factors should be considered such as, the emotional trauma and pain associated 
with injections, the risk of needle-related injuries, patient compliance and even the safe 
disposal of the needles [3]. In addition, the administration of the injection requires special 
training and expertise. 
Transdermal drug delivery (Transdermal Drug Delivery System, TDDS), a topic 
that as gain a lot of attention in the past years, appears as a valid alternative to the 
traditional methods, providing control over the rate of drug release. TDDS is a system 
that can provide what the other two methods cannot: it bypasses the digestive system and 
it does not have the same disadvantages of hypodermic injections. Besides, the skin 
contains a large number of antigen-presenting cells (i.e., Langerhans cells and dermal 
dendritic cells), becoming a suitable way for drug delivery [6-8].  Drug patches and 
microneedles (MN) have been both thoroughly investigated [2, 3]. The first transdermal 
system for systemic delivery was approved for use in the United States in 1979, a three-
day patch that delivers scopolamine to treat motion sickness [7]. Ten years later, nicotine 
patches become the first transdermal blockbuster, raising awareness to the transdermal 
delivery in medicine and for the general public [4, 5]. The main difference between the 
two types of transdermal delivery systems is that patches are limited to a restrict amount 
and nature of drugs, while MN are compatible with a wide range of drugs being also more 
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efficient in the delivery process [1]. Instead of relying on skin permeability, MNs 
physically introduce the drug into the body, accessing the epidermal and the top of the 
dermal layer of the skin. This is of major importance, as it means that the microneedles 
are short enough to avoid the nerve endings, causing no pain. The dimensions of MNs are 
lower than 1500 micrometer in length and, in the range of 50-250 and 10-25 micrometers 
in width and tip diameter, respectively. 
Besides the above mentioned, MNs provide a number of other advantages: (i) 
lower concentrations can be used since the drug release is controlled, providing a precise 
dosage; (ii) it’s a method that requires no special qualifications for administration, 
opening the way to auto-administration; (iii) due to its micrometric size, can be produced 
in large quantities, reducing the manufacturing cost and; (iv) provides total release of the 
drug maintaining its stability, among others [9, 10]. 
Three major types of MN are commonly described in the literature, depending on 
the drug and application: solid (which include coated and dissolving microneedles), 
hollow and porous [10]. Besides that, MN based material has also a significant influence 
on their effectiveness. Several materials are already used to produce MNs, including 
biodegradable polymers [11], metals [12], soluble sugars [13], glasses and ceramics [14]. 
Polymeric MN are easily shaped but have a low mechanical strength [4], whereas metallic 
MN have a high production cost and could have compatibility issues with the drug. 
Therefore, finding a material that can be tailored to better suit the desired characteristics 
and properties while reducing production cost, is still required. 
Ceramic materials appear as a new alternative to the existing options. Properties 
such as high mechanical strength, biocompatibility, and reusability (ceramic materials 
can sustain high temperatures without deformation, so sterilization is a viable option) are 
of interest and draw increasing attention to the use of ceramic materials in the production 
of MNs. Research conducted by Luttge et al. showed promising results in the 
development of ceramic nanoporous microneedle arrays (npMNAs) for the controlled 
release of drugs and vaccines [4]. In this study, alumina based npMNAs have been 
prepared by micromolding followed by sintering at 1500 ºC [15] to create nanoporosity. 
The authors showed that drug nanoparticles up to 100 nm can be loaded into the npMNAs 
and released with success in 30 minutes upon incubation in PBS [4]. Since drug loading 
in npMNAs is evaluated after sintering, the amount of drug absorbed is dependent on the 
pore size and pore size distribution and surface absorption capacity of the npMNAs. 
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Finding a manufacturing process where the drug could be added during casting process 
could be highly advantageous.  
In fact, ceramic-based components are commonly submitted to a sintering step, 
where the material is thermal treated at high temperatures (≥1000ºC), to create a 
mechanically strong solid. Besides increasing the manufacturing costs, sintering step 
avoids the incorporation of pharmaceuticals during processing, since drug molecules 
cannot withstand such high temperatures. To overcome this, the sintering step must be 
eliminated in order to fabricate ceramic materials capable of incorporating 
pharmaceuticals, while retaining its mechanical strength and drug delivery capabilities. 
In a recent study evaluated by B.Cai et al. [16], self-setting bioceramics were introduced 
as an alternative to the above ceramics. By eliminating the sintering step, the damage 
caused to the loaded drugs by the high temperatures was avoided, while maintaining the 
required mechanical strength in order to pierce skin. Brushitic microneedles loaded with 
Zolpidem tartrate to treat insomnia were successfully prepared by micromolding. Being 
a first-of-its-kind essay involving self-setting ceramic microneedles as a vehicle for 
controlled drug delivery, this study opens new opportunities for advacing with research 
in self-setting MN. Although being an innovative work, several questions need to be 
answered in what concerns manufacturing costs, formulations and real world day-to-day 
viability. 
Thus, the present work will try and shed some light on the subject, exploring the 
production and characterization of apatitic and brushitic calcium phosphate porous 
microneedles and how they behave as a controlled delivery system of an antibiotic 
(levofloxacin). 
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1. Theoretical Introduction 
1.1 - The skin 
The human body is a complex system composed of different organs and systems. The 
human skin is the largest organ of the integumentary system (organ system composed by the 
skin, hair and nails) composed of up to seven layers of ectodermal tissue that guards the 
underlying bones, ligaments, muscles and internal organs, as well as, several structures called 
appendages (hair follicles and glands). Surrounding all the human body, the skin is the interface 
with this environment, playing an important role in immunity and protecting the body against 
pathogens and excessive water loss. Other functions include insulation, temperature regulation, 
sensation, synthesis of vitamin D and regeneration. This system can be divided into two types 
of skin: hairy skin (with hair follicles and sebaceous glands) and glabrous skin (a skin type on 
the palms and soles and lacks hair follicles). 
1.1.1 - Structure of the skin 
Three layers of the skin can be recognized: epidermis, dermis and hypodermis, as illustrated in 
Figure 1. A healthy interaction between the layers is important for the maintenance of 
homeostasis in the adult. In this section, each layer will be considered separately.   
Epidermis 
The epidermis is the outer most layer of the skin (50 to 100 μm) that is divided into the 
following sublayers (Figure 2), from top to bottom [17]: 
Figure 1- Cross-section of the skin, showing it 3 main layers, as well as, some of its 
constituents. 
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 Stratum corneum (SC): consisting of mainly keratinocytes (approximately 90-95% of 
epidermal cells) containing a protein known as keratin. The thick layer (10 to 20 μm thick) 
provides a major barrier against water loss and permeation of environmental substances, as 
well as contributing to mechanical protection; 
 Stratum lucidum: this sublayer is present in the thick skin of palms and soles and 
consists of a thick layer of dead cells, functioning as a barrier and having water proof 
properties; 
 Stratum granulosum: also known as the granular layer, mainly consists of stratified cells 
arranged in one to three rows. Besides the palms and soles, the skin lacks a well-defined stratum 
lucidum and stratum granulosum; 
 Stratum spinosum: formed by cuboidal cells arranged in multiple layers, it has the 
capability to synthesize keratin; 
Stratum basale or Stratum germinatum: this sublayer consists of tall columnar cells that 
are constantly undergoing cell division and help form new keratinocytes that will replace the 
dead ones form the stratum corneum.  
This outmost layer of the skin contains no blood vessels, so cell nutrition is made almost 
exclusively by diffused oxygen from the surrounding air and, to a slighter degree, by blood 
capillaries extending to the outer layer of the dermis. Merkel cells and keratinocytes are the 
main type of cells which make up the Epidermis, with melanocytes (pigment producing cells) 
and Langerhans cells (dendritic immune cells) also presented [18].  
 
Figure 2- Diagram of the epidermis. From: (R. Randall Wickett and Marty O. Visscher) [18]. 
Epidermis 
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Dermis 
The dermis or corium is a thick layer of skin (1 to 2 mm) that lies between the epidermis 
and subcutaneous layer, sustaining and supporting the epidermis. It is composed of two 
sublayers, the more superficial papillary dermis and the deeper reticular dermis. The papillary 
dermis consists of loose connective tissue containing capillaries, elastic fibers, reticular fibers 
and some collagen. The reticular dermis consists of a thicker layer of dense connective tissue 
containing larger blood vessels, closely interlaced elastic fibers and bundles of collagen fibers 
arranged in layers parallel to the surface. The deep surface of the dermis is highly irregular and 
borders the subcutaneous layer, which additionally cushions the skin [19]. 
 
Hypodermis 
Also known as the subcutaneous tissue, this layer lies below the dermis and serving as 
a connection to the underlying bone and muscle, supplies the upper layers with blood vessels 
and nerves and insulates the body. Consists mainly of loose connective tissue and elastin, 
allowing for its mobility over underlying structures [17]. 
 
1.1.2 - Permeability of the skin 
A variety of different compounds gets into contact with the skin every day, through the 
use of household chemicals, application of cosmetics or pharmaceutical products or even by 
accident. Some of those chemicals may be absorbed or facilitate the absorption of other kinds 
of harmful components. 
The stratum corneum (SC), being the outmost layer of the epidermis, acts like a barrier 
preventing the penetration of molecules to the lower layers [18]. The SC is often compared to 
a brick wall [20], where  the corneocytes (keratinocytes) are like  the “bricks” and the layers of 
lipids between the cells like the “mortar”. This lipidic “mortar” layer is released by the 
keratinocytes, filling the gaps between them and preventing water from passing through. The 
very specialized “bricks and mortar”, work together to produce a layer that is both flexible and 
protective [21, 22]. Some molecules, like lipid soluble molecules, are able to diffuse through 
the lipid “mortar”, bypassing the barrier, but that’s not the case for all molecules. Delivery of 
a drug or a cosmetic into and through the skin involves a number of steps including release 
from the vehicle, partition into the skin and subsequent movement through the SC [23]. A 
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complete agreement still does not exist on whether lipid layers or corneocytes are the main 
contributor to the permeability barrier [24]. Penetration studies and mathematical models [24-
29] have demonstrated that the SC behaves like a passive diffusion barrier, being necessary 
additional chemicals to facilitate the diffusion though this layer, as the diffusion rate is highly 
dependent on the molecular weight and lipophilicity of the molecules [25]. Alternatively, 
mechanical penetration of the upper layer of the skin bypasses this problem. However other 
different problems arise related to the vehicle of delivery, its resistance, composition, 
biocompatibility, and general discomfort related to the application.  
 
1.1.3 - Mechanical properties of the skin  
The mechanical and biomechanical properties of the skin are of extremely importance 
to its health and disease, structural integrity, and aging. Studies about this subject began in the 
19th century [30], further underlying its importance. Investigations in the fields of plastic 
surgery [31-33], skin cancer [34-36], cosmetics [37-39] and skin aging [40,41] further 
contributed to the understanding of the biomechanical properties of the skin. 
Optical coherence electrography (OCE), also known as Optical coherence tomography 
(OCT) has been used to deduce mechanical properties in tissues [42, 43]. Introduced by Schmitt 
in 1944 [44], this technique was first used to assess the tissue biomechanics through the 
measurement of localized deformation and strain inside a sample. Further advances [45-48] 
enabled OCE to assess and extract different parameters of the tissue deformation with high 
accuracy and to reconstruct the tissue’s biomechanical properties [49]. In a study evaluated  by 
Xing Liang and Boppart, OCE was used to determine the mechanical properties of the skin 
under different conditions (normal, hydrated and dehydrated), revealing that the stratum 
corneum has a Young modulus of 101.20 kPa for normal skin, 21.01 kPa for hydrated skin and 
300.41 kPa for dehydrated skin, confirming that the mechanical strength of the skin is directly 
correlated to its hydration [31]. 
 
1.1.4 - Skin Penetration 
Knowing the mechanical properties of the skin is of the upmost importance when drug 
delivery is done through the skin. As mentioned above, the stratum corneum acts as a barrier 
that needs to be penetrated to efficiently deliver pharmaceuticals to the bloodstream. Structures 
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like microneedle arrays, made from different materials, can be used to pierce the skin 
effectively [50]. The force needed to achieve this is a subject that has been investigated [51], 
being a parameter that not only affects the penetration depth but also the force that an array can 
handle.  
In the study presented by Ryan F. Donnelly et al. [52], OCT was used for the first time 
to investigate the effect of a microneedle (MN) geometry and applied force upon penetration 
into neonatal porcine skin in vitro using poly(methylvinylether-co-maleic anhydride) 
(PMVE/MA) MNs. The research work shows that MN height can influence the extent of drug 
delivery across the skin and that higher application force corresponds to a higher penetration 
depth, as expected.  
Romgens et al [53] monitored both the penetration depth and force of single solid 
microneedles with various tip diameters. The authors shown that sharp microneedles are 
essential to insert them in a well-controlled way to a desired depth. 
Shape, geometry, tip diameter, mechanical strength and based materials are all parameters 
that need to be considered in order to create a device that can easily deliver pharmaceuticals 
through the skin. Microneedles appear as a suitable solution for transdermal drug delivery [9, 
54-56], as discussed in the next section. 
 
1.2 - Microneedles  
For many years, hypodermic needles have been the most used technique for transdermal 
drug delivery. However, recent discoveries and advances in the biotechnology field showed 
that this delivery system has several limitations and disadvantages [11, 16]. As soon as new 
ways to fabricate microneedles for transporting nano-size molecules are discovered, the use of 
hypodermic needles could be discarded for certain applications, since they cause discomfort 
and limit the range of delivery.  
Microneedles can be divided in three categories: solid microneedles, hollow 
microneedles and porous microneedles, as schematically shown in Figure 3. In turn, solid 
microneedles include: (i) the ones used to create porosity in the skin prior to drug 
administration, (ii) drug-coated solid microneedles where the drug is dissolved by the skin and 
the MN patch subsequently removed, and (iii) dissolving MN where complete patch containing 
drug molecules is adsorbed by the sky. Hollow Microneedles are considered the most 
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challenging ones in terms of fabrication, due to the presence of a fine hole (50-100 m) in their 
middle, and can be used to deliver liquid-like drugs.  In porous MN, drug is usually captured 
in the pores and released by diffusion mechanisms after skin penetration [10]. 
This work, will be essentially focused on porous microneedles, its composition, 
geometries, fabrication methods and applications. 
 
1.2.1 - Solid microneedles  
1.2.1.1 - Materials used in the fabrication of solid microneedles 
One of the first strategies for the transdermal drug delivery is based on the use of solid 
MNs, where the microneedle array is first applied to the skin, creating micro-channels that 
allow the subsequently application of the drug [10]. However, some limitations of this method 
are clear: (1) a two-step process is needed, which may lead to practicality issues to the end user, 
(2) limited to certain type of drugs (usually cosmetics), between others. 
Several materials have been used to produce MNs capable of transdermal drug delivery. 
Considering solid MNs, silicon [58], metals, polymers [59] and ceramics [19, 20] have been 
used as based materials. While being a high throughput manufacturing method, 
microfabrication methods for most of the MNs (silicon, metals, polymers based) are often 
expensive, highly specialized and include complex multi-step processes [11, 21]. Standard 
Figure 3- Different types of microneedles according to their structure and drug delivery 
mechanisms [4]. 
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metals usually utilized in the medical practice, such as stainless steel and titanium, have also 
been used as structural materials for solid MN fabrication [22-25], mainly because such 
materials should not raise any issues of safety, facilitating the regulatory pathway to 
commercial acceptance.  Polymers are a viable alternative when compared to metals or silicon, 
although mechanical properties are usually poor.    
Developing a complex structure in the micrometer scale such as a microneedle array is 
not an easy task. Furthermore, obtaining MN patches at an affordable cost implies the use of 
cost-efficient manufacturing processes. Among the high tech processes used in microneedle 
manufacture, such as, laser cutting [66], lithography [67] and wet and dry etching [68], micro 
molding is the most explored one for MN fabrication [69]. However, as in all replication 
methods, the first and most crucial step is to create a master structure, to obtain the mold 
(usually PDMS, polydimethylsiloxane, based) where the desired structure will be shaped. 
Although the requirements for the master structure differ with respect to the physical 
parameters of the chosen replication method, four basic statements are common [69]:  
(a) The geometrical replication result can only be as good (or as bad) as the geometrical 
accuracy of the master; 
(b) For the ability to separate mold and molded part (demolding step), no undercuts in the 
structure itself can be allowed; 
(c) The surface roughness of the master should be as low as possible; 
(d) A suitable interface chemistry between master and substrate must be chosen. 
The prevailing technique used for fabricating PDMS devices involves master creation 
by a process called photolithography [70], which is a time consuming, multi-step and expensive 
process that needs to be carried out in a clean environment. While mold replication from the 
master could be an easy and costly efficient process, master fabrication involves the use of 
expensive advanced processing technologies. Eliminating the need for a master in micro 
molding fabrication could steeply decrease the total cost of the fabrication process, as well as 
its complexity. Hamsapriya et al. [71] published a study reporting the use of laser pulses to 
directly fabricate 2D and 3D structures in micro-scale on PDMS. Using a short pulse-to-pulse 
laser capable of achieving localized rapid heating (femtosecond laser) directly on thin PDMS 
layer, Hamsapriya et al. created a single-step masterless fabrication of PDMS microstructures.  
Taking advantage of casting techniques in PDMS micro molding, ceramics have been 
recently explored for MN fabrication [15, 60, 61, 72]. Gel casting was mentioned in literature 
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as a capable technique to fabricate this kind of micro components with complex geometries 
and dimensions lower that 1 mm [26, 27]. For that, ceramic suspensions parameters, such as 
solids loading, pH [74], surface chemistry [75] and interactions between ceramic particles with 
the dispersing agent [76] are of major importance and need to be precisely controlled in order 
to obtain the desired MN properties [60]. While in gel casting process of macro components, 
different gelling agents can be used, for micro component fabrication specific requirements 
should be addressed. The system “epoxy resin plus hardener”, presented by Olhero et al. [60], 
has been proved to be adequate to obtain low viscosity suspensions during mold casting, to 
guarantee complete filling of the microparts, as well as high green strength (around 35 MPa) 
to de-mold them without damaging. Olhero et al.[60], highlighted for the first time, the 
relevance of the specific interactions between processing additives and oxide particles having 
different surface chemistries (alumina, silica and zirconia) in determining the kinetics of curing 
and the properties of green bodies consolidated by Epoxy Gel Casting (EGC) process. The 
work developed by Olhero et al. demonstrated that EGC is a promising technology for the 
microfabrication of ceramic components with complex shapes and sharp features, opening a 
new way for fast replicating and cost-efficient production of MN.  Since ceramic MN obtained 
by this method should be sintered after de-molding, EGC was considered a promising 
technique for fabrication hollow ceramic microneedles for drugs administration in liquid form. 
 
1.2.1.2 - Self setting ceramic MN 
Even if ceramics could have some advantages when compared to polymers for MN 
applications, sintering procedure make them less attractive, not only due to the increase of 
manufacturing costs but also to the limitation in drugs incorporation before this step. To 
overcome this restriction, self-setting ceramics appear as alternative materials. Developing 
solid MNs from calcium phosphate based cements is a new research field, with only one paper 
published about the subject till date [16] (from author knowledge). In this study, Bing Cai et 
al. [16] explored the use of self-setting bioceramics for drug delivery, using Zolpidem tartrate 
as a model drug. Self-setting microneedles were fabricated from calcium phosphate based 
cements under ambient conditions to minimize drug degradation during fabrication and to 
facilitate a higher drug loading capacity. The drug release study showed that the release rate 
from this type of MN array could be controlled by the bulk surface area, porosity and resorption 
rate of the ceramic needles. Moreover, the needles proved to be capable of piercing the stratum 
corneum of the porcine skin. Promising results were obtained with this study opening the 
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opportunity to deeply explore the fabrication of MN by self-setting ceramics and their 
capability to deliver drugs throughout the skin. 
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1.3 - Calcium phosphates 
Calcium phosphates (CaPs) are the most important inorganic constituents of biological 
hard tissues. In the form of carbonated hydroxyapatite, they are present in bone, teeth and 
tendons to give to these organs stability, hardness and function. Calcium phosphate crystals are 
also found in nature as mineral deposits in considerable amounts, growing over the years, 
sometimes in extreme conditions of pressure and temperature. In contrast, biologically formed 
calcium phosphates are often nanocrystals precipitated under mild conditions (ambient 
pressure, near room temperature) [77].  
Apart from calcium pyrophosphate (Ca2P2O7), most calcium phosphates, previously 
used in vivo as bone substitutes in various forms, were calcium orthophosphates (presence of 
the orthophosphate group PO43-), commonly named calcium phosphates (Table 1).  
Table 1 -Some calcium phosphate compounds, their Ca/P ratios and symbols [78]. 
Name Formula Ca/P Symbol 
Monocalcium phosphate 
monohydrate 
Ca(H2PO4)2.H2O 0.50 MCPM 
Dicalcium phosphate dihydrate CaHPO4.2H2O 1.00 
 
DCPD 
Calcium deficient hydroxyapatite Ca10-x(HPO4)x(PO4)6-
x(OH)2-x 
1.50-1.67 
 
CDHA 
Amorphous calcium phosphate Ca3(PO4)2.nH2O   
α-Tricalcium phosphate α-Ca3(PO4)2 1.50 α-TCP 
β-Tricalcium phosphate β- Ca3(PO4)2 1.50 β-TCP 
Sintered hydroxyapatite Ca5(PO4)3OH 1.67 HA 
 
Among the numerous calcium phosphate compounds, only the precursor compounds used 
in this work will be referred and highlighted. 
MCPM is the most soluble and acid for almost all pH levels [78]. It can be obtained by 
chemical precipitation from highly acidic solutions at room temperature with a crystalline 
structure similar to thin blades [79]. At temperatures above 100 ºC, a water molecule is released 
and MCPM is transformed into MCPA (anhydrous monocalcium phosphate). Due to his acidity 
and solubility, MCPM is not biocompatible, although it can be used in combination with other 
basic calcium phosphates for the production of several calcium orthophosphate cements [78], 
[79]. 
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Many calcium phosphate cements (CPC) have been proposed as bone substitutes, some 
based on the use of tricalcium phosphate (Ca3(PO4)2, TCP) [80]. TCP has three polymorphs 
[81] depending on the temperature, The low temperature β-TCP phase (rhombohedral structure 
- space group R3cH and theoretical density, 3.07 g.cm-3) is obtained by thermal decomposition 
at temperature above 700-800ºC [82] and is stable up to 1125ºC. Above this temperature, α-
TCP is transformed with volumetric expansion into the monoclinic α-TCP phase (theoretical 
density, 2.86 g cm-3), which has a complex crystal structure with the space group P21/a. α-TCP 
is stable between 1125°C and around the temperature range of 1430ºC [83] - 1475 °C  (as 
shown in phase diagram of Figure 4), and it can be maintained at room temperature as a 
metastable phase.  
The α´-TCP is stable above 1430°C – 1475ºC until the melting point of 1765ºC and is 
unable to survive quenching to room temperature [9-11].  
Phase transformation through thermal treatment is the most direct way of obtaining pure 
α-TCP from β-TCP [84], but is also a challenging one. Small quantities of β-TCP  [78-82] 
and/or HA [85-87] in the final product have been reported, resulting in non-pure, and therefore, 
unwanted biphasic composition. The presence of β-TCP as second phase is attributed to a 
partial reversion during cooling of the already formed α-TCP phase [88]. As the polymorphic 
Figure 4- Phase equilibrium diagram for the CaO-P2O5-H2O system (C=CaO; 
P=P2O5; Ap=apatite) according to Riboud-[150]. 
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β→α-phase transformation is considered to be reconstructive  [85-87], the reverse α→β-TCP 
transformation would require surpassing a considerable activation energy barrier to proceed 
[89]. Considering this, reverting α→β-TCP should only be possible under a very slow cooling 
rate or a long dwell at a temperature below the transformation temperature. Rapid cooling 
techniques such as quenching [88-89] or a moderate to high cooling rate [89] (5ºC/min [92] 
and 10 ºC/min [93]) are suggested as a solution to maintain the desired α-TCP purity.  
Besides the influence of temperature in phase conversion, some studies have showed 
that slight variations in Ca/P ratio (Ca/P=1.50) of TCP also affect α-TCP purity, as shown in 
the phase diagram presented above (Figure 4). These variations lead to the formation of small 
amounts of HA (positive variation, Ca/P > 1.50) or CPP (calcium pyrophosphate, negative 
variation, Ca/P < 1.50), as seen in Figure 5. Minor amounts of CPP are known to strongly affect 
the α↔β-TCP phase transition, as shown by Bohner et al. [93],  Welch and Gutt [94], and more 
recently by Torres et al. [95]. Starting from a -TCP powder with a trace of CPP to obtain 
pure-TCP powder is compromised, with strong possibility to have in the final product -TCP 
as secondary phase, which amount varies according to the cooling rate imposed on the 
calcination cycle. 
As shown by the work of Destainville et al. [96], a tight control over experimental 
conditions during the synthesis process, such as pH and temperature, greatly influence the 
resulting product. Figure 5 shows the Ca/P molar ratio versus the ripening time of powder 
synthesized at different temperature and pH values. For a temperature of 30ºC and pH 8, a Ca/P 
Figure 5- Ca/P molar ratio of precipitates vs. ripening time for different synthesis 
conditions of aqueous precipitation method according to Destainville et al. [96]. 
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> 1.50 is obtained in the first 4 hours, insuring that no CPP is formed and the α→β-TCP 
regression does not occur after thermal treatment. 
β-TCP and α-TCP have been extensively used in medical applications due to the 
biodegradable and biocompatible properties [78, 97]. Considering its biological interactions, 
α-TCP is non-toxic, osteoconductive and bioactive. Although its biodegradability is higher than 
β-TCP and HA, it is less stable and as so, more reactive [98]. Calcium phosphates can also be 
categorized by one of their most important characteristics: solubility in aqueous medium. As 
so, depending on its chemical composition and porosity, CaPs can be organized by its 
degradability (ordered from more to less degradable) [78]: 
MCPM > α-TCP > DCPD > DCP > β-TCP > HA 
Properties like tension, compression force and stress resistance are also parameters 
highly dependent on the chemical composition and the porosity of the material that influences 
also its applications [99]. 
 
1.3.1 - Calcium phosphate cements 
CPC’s were first discovered by Brown and Chow in the 1980’s [100]. Despite a large 
number of formulations, CPC are divided into two different end-products: apatite (CDHA) and 
brushite (DCPD) [78]. These synthetic biomaterials are formed from a mixture of a solid 
component and an aqueous solution, both reacting at room temperature to obtain a paste that 
contains one or more types of calcium phosphates [101], as summarized in the diagram 
presented in Figure 6 [102]. 
 
Figure 6- Preparation of a CPC. Adapted from: (Driessens, 1997) [102]. 
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After mixing powder with liquid, a plastic paste is obtained, increasing viscosity as 
setting time increases, losing its malleability and ability to deform. During setting reaction, the 
calcium phosphates dissolve and precipitate into a less soluble CaP phase(s). The precipitated 
CaP crystals grow and become entangled, providing rigidity to the cement [78]. The chemical 
reaction occurring during the setting times of the CPCs is highly dependent on its chemical 
composition, and can be divided into two main types of reactions [103]: 
(A) Acid-base reaction, as for example when the neutral β-TCP reacts with the acidic 
MCPM forming DCPC, as shown below (equation 1): 
β-Ca3(PO4)2 (s)+ Ca(H2PO4).2H2O (s)+ 7H2O (l) – 4 CaHPO4.2H2O (s) (1) 
(B) Hydrolysis, when for example α-TCP is mixed with an aqueous solution, forming 
CDHA, or calcium deficient hydroxyapatite (equation 2):  
3 α-Ca3(PO4)2 (s) + H2O (l) – Ca9(HPO4)(PO4)5(OH) (s)   (2) 
 
1.3.2 - Apatite CPCs 
Since the discovery of CPCs [100], numerous formulations have been proposed. Most 
apatite CPC formulations have CDHA as the end-product of the reaction, having all of them a 
long intrinsic setting time [78]. The mechanical properties of the apatite CPC highly depend 
on its composition and can widely vary. The main factor is the ratio between the amount of 
setting liquid (L) and cement powder (P) that varies directly with the CPCs porosity (low L/P 
ratio results in low porosity), resulting in lower mechanical properties as the porosity increase. 
Considering the excellent biocompatibility of apatite CPCs, applications for drug delivery can 
be considered, as the CPC will not cause inflammatory response when in contact with skin 
[86]. 
 
1.3.3 - Brushite CPC 
DCPD is the product of the setting reaction of so-called brushite cements. These types 
of cements where introduced by Mirtchi and Lemaitre in 1987 [35, 36], where the DCPD is a 
result of the β-TCP + MCPM reaction, as shown previously in equation (1). Several 
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formulations to obtain brushite cements have been proposed, such as β-TCP + H3PO4 [97], 
[105] and β-TCP + MCPM + CaO [106]. According to Bohner et at. [105], the first formulation 
has some advantages over the second one: (i) rapid and easy preparation, (ii) better control over 
the chemical composition and reactivity, and (iii) better physical and chemical properties such 
as enhanced setting times and better tension resistance [105]. 
All brushite CPC are obtained via acid-base reaction, meaning that the paste is acidic 
during the setting reaction, since brushite only precipitates around pH < 6 [37, 39]. 
Brushite CPCs are biocompatible, bioabsorbable and rapidly degraded (in vivo 
conditions), due to their solubility [107] although the porosity has its influence. The high 
growth rate of the brushite crystals results in a low setting time, making it a material not suitable 
for certain clinical applications [108]. To somewhat compensate this flaw, additives such as 
citric acid [109] and glycolic acid [110], that inhibit the growth of DCPD crystal have been 
used to increase the setting time of the brushite CPCs.  According to Román et al. [111] the 
hardening reaction (the complete formation of the crystals) of brushite has the duration of 
around 24 hours, for a Ca/P of 1.50 and using citric acid as liquid phase, although having a 
high initial reactivity. This is probably due to the fact that, at the end of the setting reaction, 
the pH level of the mixture increases, which causes a decrease in the solubility of the reagents 
[97]. 
1.3.4 - Apatite CPCs vs Brushite CPCs 
Although both apatite and brushite cements are commercially available due to their 
usefulness for the reconstruction of bone defects, their behaviors in the bone defect are quite 
different especially in respect to resorption. Brushite cement resorbed much faster when 
compared to apatite one. This difference is caused by the compositional difference in the final 
products. As the name represents, final product of apatite cement is apatite, whereas final 
product of brushite cement is brushite being apatite the most thermodynamically stable phase 
at physiological conditions. Since the human body-fluid is supersaturated in ions of apatite 
phase, no physicochemical dissolution occurs in the case of the apatite cement (at physiological 
conditions) [112].  
Brushite is the most stable phase at pH values in the range of 2.0–4.2 being formed 
based on dissolution-precipitation reaction and entanglement of the brushite crystals during 
setting reaction. However, brushite is a metastable phase at physiological pH and dissolves 
upon exposure to the body fluid [112]. 
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Nonetheless, brushite cement dissolves much faster than apatite cement. As an example, 
Apelt et al.[113] reported that brushite cement was used for the reconstruction of bone defects 
in sheep, and it almost completely resorbed after 6 months, whereas apatite cement did not 
show any notable change for the same time period [45, 46]. 
 
1.3.5 - Properties of the CPCs 
CPCs have wide range of properties that are tightly linked to several factors that can be 
tailored according to the application target, as shown in Table 2. The final properties of the 
CPCs depending highly on the composition of its solid phase, ratio of the components in the 
mixture, additives and particle size distribution of the powder.  
 
Table 2- Parameters that affect the properties of the CPCs. From: (Ginebra, 2008)[107]. 
Powder phase Chemical composition 
Relative proportion of its constituents 
Additives (accelerators, retardants) 
Particle size distribution 
Liquid phase Additives (accelerators, retardants, cohesion 
parameters) 
pH 
Mixing parameters Powder/Liquid ratio 
Mixture process (time, rotation) 
Environmental factors Temperature 
Humidity 
pH 
 
Particle characteristics 
The particle characteristics of powder phase heavily influence initial and final 
properties of CPC. Particle size and size distribution, shape and specific surface area are the 
four major influences of powder phase on the behavior of the CPCs. Particle size is directly 
related to the setting time and consequently to the mechanical properties of the CPC. For a 
given liquid to powder ratio setting time decreases as particle size decreases, since smaller 
particles dissolve faster and the precipitation process of the new phase begins earlier [93]. 
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Liquid phase 
The liquid phase composition in a powder-liquid mixture is also an important factor that 
influences final CPCs properties. The liquid is a vehicle for the dissolution of the reagents and 
for the precipitation of the final products of the reaction. This aqueous phase can be just 
composed of distilled water or can contain many organic or inorganic additives that can be 
used to tailor CPCs properties. These additives can influence the setting time, rheological, 
cohesive properties and porosity of the paste/cement, for example: 
 Sodium hydrogenophosphate (Na2HPO4) [114]: accelerates the hardening process, 
lowering the setting times in apatitic cements; 
 Citric acid (C6H8O7)[109]: (1) slows the reaction time, increasing the setting time in 
brushitic cements; and (2) accelerates the hardening process in apatitic cements, 
decreasing the setting time. 
Liquid-to-powder ratio  
The liquid-to-powder ratio (L/P) is a very important parameter than can determine 
several properties of the cement [115], such as setting time [116,117], rheological 
behavior[115] and mechanical strength [98, 117]. Higher  L/P ratios lead to a decrease in 
mechanical strength and higher initial (IST) and final (FST) setting times, which can be 
explained by the increase in porosity caused by the higher amounts of liquid phase [98,117]. 
Setting time 
Setting time is defined as a specified time required for a paste/cement to change from 
liquid state to plastic state (initial setting time, IST) and plastic state to solid state (final setting 
time, FST), so that the surface becomes sufficiently rigid to withstand a defined amount of 
pressure [118]. It’s a continuous process that can be described in three steps [119]: 
1. Dissolution of the reagents; 
2. Nucleation of the newly formed crystals; 
3. Growth of the newly formed crystals. 
There are two methods used to determine IST and FST of a cement, the Gillmore needle 
test [Standard Test Method for Time of Setting of Hydraulic-Cement Paste by Gillmore 
Needles, ASTM C266-15] and the Vicat needle test [Standard Test Methods for Time of Setting 
of Hydraulic Cement by Vicat Needle, ASTM C191-13]. Both of these tests follow the same 
methodology, analyzing the surface of the cement to assess if the needle produces an indent 
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after contact [120]. The Gilmore needle test is more widely used, consisting of two different 
needles: (1) a thick and light needle to assess the IST and (2) a thin and heavy to determine the 
FST. The Vicat needle test, on the other hand, uses only one needle at a time to determine the 
IST or FST.  
Evaluating the setting times of a cement is essential to determine its handling time of a 
cement past. For the molding process, up until the IST, the cement is malleable, so it can be 
deformed and molded to a desired shape. When the compound is in the desired shape and the 
hardening process is yet to be completed, it cannot be handled without the risk of producing 
fractures along the structure. The FST indicates when the hardening process is finish and the 
sample can be handled without damaging it. As in other properties, setting time can be 
influenced by different factors of the mixture (liquid and solid phases) as well as ambient 
conditions [107]:  
i) Particle size; 
ii) Crystallinity; 
iii) Composition of the liquid phase; 
iv) Temperature; 
v) Liquid-to-powder ratio. 
Mechanical Properties 
The mechanical properties of CPCs are a key property that needs to be determined to 
assess if the composition of the cement is adequate for the intended use. Generally, CPCs have 
poor mechanical properties [121-124], limiting its clinical applications. As a method of 
enhancing these properties, some authors used polymers such as gelatin [125] and short-length 
polyhydroxyalkanoate (linear polyesters produced by bacterial fermentation of sugar or lipids) 
[126]. Several factors can influence the mechanical properties of CPCs, as shown in Table 3 
[127]. 
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Table 3- Properties of CPCs that can affect its mechanical behavior. 
Property Effect 
Formulation [128] Maximum shear resistance can vary for 
formulation to formulation. 
Liquid-to-powder ratio [129] A higher L/P ratio leads to a decrease in shear 
resistance. 
Particle size [130] As the particle size decreases, the shear 
resistance increases. 
Incubation temperature [131] High temperatures can lead to the dehydration 
of the samples, weakening its structure. 
 
In a recent study published by Ingrid Ajaxon et al.[132] the compressive strength and 
elastic properties of brushitic and apatitic CPCs were measured and compared. The brushitic 
CPCs were found to be stronger than the apatitic CPCs, in good agreement with other results 
presented in  literature [80,91,103,133,134]. 
Porosity 
Water is a major intervenient in the setting reaction of CPCs, as shown in previous 
equations (1) and (2). As a result, not all the water is consumed during the hydration phase, 
resulting in a porous structure.  The porosity of CPCs is directly related to the L/P ratio used 
varying between 30% and 50%. Particle size distribution of the starting powders and particles 
packing behavior can also modify the microstructure, as well as the pores size and size 
distribution [135]. Techniques such as mercury intrusion porosimetry (MIP) [136], gas 
adsorption and thermoporometry (TPM) [137]  and have been used to determine the porosity 
of CPCs [138]. 
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2. Materials and Methods 
In order to better understand how this thesis was conducted, the experimental work will be 
divided into five stages of production. Each stage includes the characterization techniques that are 
required to either move forward to the next stage or to better understand its results. Stages are divided 
as follows:  
Table 4- Description of the different stages of the developed work 
 
 
 
 
 
 
 
 
 
 
 
 
2.1 - Stage 1: Synthesis of CaP based powders 
To obtain brushitic and apatitic cement pastes, TCP (-TCP powder) and BTCP 
(biphasic powder, mixture of β-TCP and α-TCP) were used as starting materials. These CaP 
based powders where synthesized via wet chemical precipitation method according to previous 
works [127].  
The synthesis process starts with the preparation of aqueous solutions (deionized water) 
of diamonium hydrogenophophate, ([(NH4)2HPO4.4H2O], Panreac, Spain) and calcium nitrate 
tetrahydrate, ([Ca(NO3)2.4H2O], Panreac, Spain) as phosphorous and calcium precursors, 
respectively. In order to obtain a Ca/P ratio of 1.51, a 0.6M of P solution was used and the Ca 
concentration was adjusted accordingly. Although the theoretical value of Ca/P ratio to obtain 
pure β-TCP is 1.50, a Ca/P ratio of 1.51 was used to ensure that no β-CPP (calcium 
pyrophosphate) was formed. The solutions were mixed inside a reactor at 30ºC and stirred at 
700 rpm for 4 hours. The pH levels were monitored in real time, as described below. pH was 
adjusted to 7-8 using an ammonia solution (25% NH3, Sigma-Aldrich, Germany) with a final 
 Description Characterization techniques 
Stage 1 Synthesis of CaP based powders  pH and temperature monitoring 
Stage 2 Calcination and milling of powders Particle size and size distribution 
Crystalline phases 
Stage 3 Preparation and moulding cement pastes with and 
without drug 
Setting time 
Mechanical properties 
Porosity and density 
Crystalline phases 
Microstructural analysis (SEM) 
Stage 4 
 
 
Stage 5 
Antibiotic distribution and release studies 
 
 
Microneedles fabrication 
Raman Confocal 
UV 
 
SEM  
Mechanical properties 
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added volume ranging from 100 mL to 150 mL. After 4 hours, the precipitate was vacuum 
filtered and dried at 100ºC for 72h.  The full process is schematically presented in Figure 7. A 
total of nine synthesis were performed, hereafter denominated as S-I, S-II, S-III, S-IV, S-V, S-
VI, S-VII, S-VIII, S-IX, in order to have enough powder for the desired assays, resulting in 
200-250 g of powder per synthesis.  
 
 
2.1.1 - pH and temperature monitoring  
As described in previous works [127], experimental conditions such as Ca/P ratio,  
synthesis time, pH and temperature, are essential to obtain the desired powder composition. 
For the standard synthesis conditions available in the lab, the pH is not continually measured 
and the temperature evaluation is relied on the oil bath recirculation to maintain the targeted 
30ºC within the reactor. Since small fluctuations in pH could influence the final products, a 
data logger (DrDAQ, PICO) coupled with a pH sensor (DD011) connected to a laptop running 
a logging software (PICOlog) were used in order to monitor the pH in real time, obtaining 
values every second (Figure 8). This allowed a more precise control over pH conditions and an 
overall optimization of the reaction, raising the number of control points from 30 to 14400. 
Regarding temperature, it was monitored by a digital thermometer equipped with a metal rod 
every 5 minutes. The obtained data (.txt file) was processed using MatLab to automate the 
process. In order to better represent the data, every 10 minutes a total of 10 control points ([-
5s, +5s]) were chosen, its average value calculated and then plotted. 
Figure 7- Schematic representation of the method used to obtain the CaP based 
powders. 
P 
precursor 
Ca 
precursor 
Precipitation Filtration Drying Calcination 1 
(pH control) 
Ammonia 
solution 
Calcination 2 
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2.2 - Stage 2: Calcination and milling of CaP based powders 
The dry precipitates were deagglomerated and then calcined. To obtain TCP, the CaP 
based milled powder was calcined in a Termolab furnace at 1000ºC maximum temperature 
with 2h holding time with a heating rate of 5ºC/min, followed by natural cooling to ambient 
temperature. To obtain BTCP, previously -TCP powder  was submitted to 1250ºC maximum 
temperature with the following schedule [127]: 10ºC/min until 1000ºC, followed 5ºC/min to 
1250ºC, with 10h holding time at this temperature with subsequent cooling to 30ºC at 20ºC/min 
rate. Figure 9 summarizes the calcination schedules used to obtain both powders. After cooling, 
both powders were milled and analyzed in terms of particle size distribution and crystalline 
phases. 
 
2.2.1 - Particle size distribution (PSD) analysis  
Particle size distribution was determined using a Coulter LS 230 (Fraunhofer optical 
model, United Kingdom), allowing a measurement of particles in the range of 0.4 µm-2000 
Figure 8- Reactor schematic. The oil bath maintains the desired temperature during the reaction (left). 
PICO data logger was used to monitor temperature and pH in real time. 
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µm. For that, the powders were dispersed in an aqueous medium with a few drops of 
deflocculant (Targon 1128, BK Giulini Chemie, Germany) for deagglomeration and ultra-
sonicated for 5 minutes at ambient temperature.  
2.2.2 - Crystalline phase 
The crystalline phases of both CaP based powders (TCP and BTCP) were determined 
via X-ray diffraction (XRD) using a high resolution diffractometer (Bunker D8 Advance 
DaVinci) with Cu-Kα radiation at a wavelength of λ=1.5406 Å, scan interval (2θ) of 5º to 70º 
and a step width of 0.0130º 2θ.s-1. The identification of the crystalline phases was evaluated 
comparing the obtained diffractogram to the standard diffractograms listed below in Table 5: 
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Figure 9 - Calcination schedules used to obtain TCP (β-TCP) and BTCP (β-TCP+α-TCP) powders. 
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Table 5 - Standard JCDD cards used for the crystalline phases identification. 
Name Symbol PDF number 
Calcium deficient hydroxyapatite CDHA 01-071-6794 
Dicalcium phosphate DCP 04-009-3755 
Dicalcium phosphate dihydrate DCPD 04-013-3344 
Sintered hydroxyapatite HA 04-015-7245 
α-Tricalcium phosphate α-TPC 04-010-4348 
β-Tricalcium phosphate β-TCP 04-006-9376 
β-Tricalcium pyrophosphate β-CPP 04-009-3876 
 
2.3 - Stage 3: Preparation and casting cement pastes with and without antibiotic 
As described in chapter 1.3, to obtain a cement paste, a solid phase is mixed with a 
liquid phase. In the present work, two cement paste compositions have been prepared to obtain 
brushitic and apatitic cements. The system -TCP + MCPM (Monocalcium phosphate 
monohydrate, [Ca(H2PO4)2.H2O], Sigma-Aldrich, Germany) mixed with citric acid aqueous 
solutions (15%, [C6H8O7], Sigma-Aldrich, Germany) was used for brushitic cements 
preparation, while BTCP mixed with 3wt% of anhydrous sodium hydrogen phosphate 
[Na2HPO4] (Merck, Germany) or citric acid (10-15%) were used to obtain apatitic or brushitic 
cements, respectively [120]. The pastes were prepared by adding the powders with different 
amounts of liquid phase according to the desired liquid to powder ratio: 0.28, 0.30, 0.34, 0.38 
and 0.40 mL.g-1. For cements loaded with antibiotic, 2.5 wt.% of levofloxacin was added to 
the paste. All pastes were then casted in different mold shapes according to characterization 
requirements (pellets, cylinders or microneedles). The molded samples were then placed in an 
oven with controlled temperature and humidity (37ºC, with a set humidity of 80%) for the time 
required for setting and subsequently de-molded and kept in the same condition for further 96 
h.  After this period, in order to study the probability of drug migration to the surface of the 
samples, two different drying processes were used: (1) cement samples were placed at 40ºC 
without controlled humidity until complete drying (oven drying, OD); (2) samples were 
immediately frozen at -80ºC for 48h and then lyophilized for 24h (freeze drying-Liof).  Figure 
10 resumes the full process. 
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The CPC formulations studied are listed in Table 6 and 7, for cements prepared from 
TCP and BTCP powder, respectively, as well as the nomenclature used for each of them.  
Table 6: CPC formulations prepared from TCP powders. 
Oven drying  
Nomenclature 
L/P ratio 
(mL.g-1) 
Citric acid  
(wt.%) 
Levofloxacin 
(wt.%) 
TCP-0.28-OD 0.28 15 - 
TCP-0.30-OD 0.30 15 - 
TCP-0.30-L-OD 0.30 15 2.5 
TCP-0.34-OD 0.34 15 - 
TCP-0.34-L-OD 0.34 15 2.5 
Lyophilization  
TCP-0.28-Liof 0.28 15 - 
TCP-0.30-Liof 0.30 15 - 
TCP-0.30-L-Liof 0.30 15 2.5 
TCP-0.34-Liof 0.34 15 - 
TCP-0.34-L-Liof 0.34 15 2.5 
 
  
Solid phase Liquid phase 
Mixing 
(1 min) 
Cylinders 
Oven Drying 
40 ºC, 80% 
Humidity 
.   .   .   .
.   .   .   .
.   .   .   .
.   .   .   .
.   .   .   .
.   .   .   .
.   .   .   .
.   .   .   .
Microneedles 
Pellets 
Freeze Drying 
-80 ºC 
Lyophilized 
or 
Figure 10- Schematic procedure of preparation, molding and drying of the cement 
samples. Each sample is prepared accordingly and then molded into the correct shape for 
the desired essay. After de-moulding, samples are either oven dried or lyophilized. 
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Table 7 - CPC formulations prepared from BTCP powder. 
Oven drying  
    Liquid composition    
Nomenclature 
L/P ratio 
(mL.g-1) 
Citric acid 
(wt.%) 
Na2HPO4 
(wt.%) 
Levofloxacin  
(wt.%) 
BTCP-0.28-HP3-OD 0.28 - 3.0 - 
BTCP-0.30-HP3-OD 0.30 - 3.0 - 
BTCP-0.34-HP3-OD 0.34 - 3.0 - 
BTCP-0.38-HP3-OD 0.38 - 3.0 - 
BTCP-0.40-HP3-OD 0.40 - 3.0 - 
Lyophilization 
BTCP-0.34-AC10-L-Liof 0.34 10 - 2.5 
BTCP-0.34-AC15-L-Liof 0.34 15 - 2.5 
 
2.3.1 - Setting time (IST and FST) 
Initial setting time (IST) and final setting time (FST) of the cement pastes were 
determined using a Gillmore needle apparatus, as stated in the norm ISO/DIS 18531:2015 (E). 
After mixture, the cement paste is poured into a silicone mold (3 cm in diameter, 1 cm thick) 
and placed in a closed box (with a relative humidity ≥70%). For IST purposes the lower weight 
needle was used while for FST was used the heavy needle.  The measurements consist in 
pouring the needle onto the surface of the cement sample every 30s and observing if an 
indentation is formed. The process was repeated until no indentation was visible in the cement 
surface, being this times IST of FST.  
 
2.3.2 - Mechanical properties 
The cement pastes were casted into cylinders (as shown in Figure 10) (Φ 6 mm, height: 
12 mm) for compressive strength measurements. For all cylinders, parallel base surfaces were 
assured (rectifying if not parallel) and its mechanical properties were tested using a Shimandzu 
Autograph (Japan), equipped with a 10 kN load cell (Figure 11). Each cylinder was placed 
between the pressure plates and compressed until failure at a strain rate of 1 mm.min-1.  
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Figure 11- Cylindrical cement samples used for compressive strength test (left) and cement sample 
ready to be tested (right). 
 
To access the force that can be applied to the microneedle tip without breakage, was used the 
apparatus presented in Figure 12 . 
  
Figure 12 - Apparatus used to access the mechanical properties of the microneedle 
tips. 
Chapter 2: Materials and Methods 
 
 
34 
 
2.3.3 - Porosity and density 
The total porosity (open and closed porosity) was determined from the real density and 
the apparent density, as shown in equation 3: 
Total porosity =  
  
 
   (3) 
where,       
 Open porosity: network of fine interconnected capillaries, connected to the surface of 
the material; 
 Closed porosity: pores with no connection to the surface; 
 Apparent density: ratio between the weight and the apparent volume of a sample. Dried 
cement samples (40ºC for 4 days) were weighted and their apparent volume determined 
according to the Archimedes principle by immersion in mercury, as presented in 
previous works [127]. The apparatus used for this measurement was presented in Figure 
13.  
 Real density: difference between the apparent volume of the sample and the total 
volume of pores (open and closed), which was determined by a Helium pycnometer 
(Multipycnometer Quantumchrome, US). For this test, dried and milled cement 
samples were used. 
 
 
Figure 13- Apparatus used to determine apparent volume of cement samples according to 
Archimedes Principle.  
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2.3.4 – Microstructural analysis  
Scanning Electron Microscopy (SEM, Hitachi S-4100, Japan), was used to determine 
the microstructural properties of the samples. The microscope is equipped with an electron 
emission system with a tungsten filament, and all the images were taken with an acceleration 
of 25 kV at different magnifications. Surface of the cement samples were observed. 
2.4 - Stage 4:  Antibiotic distribution and release studies 
In this stage of the thesis, antibiotic distribution in cement samples and release studies 
were carried out. Samples loaded with 2.5% of levofloxacin (oven dried and lyophilized) were 
analyzed via Raman using a confocal Raman microscope (WITec alpha300 RAS+ (WITec, 
Ulm, Germany). An Nd:YAG laser operating at 532 nm were used as excitation source, with 
the power set 5mW (150 x 150 points per grid in a 50 x 50 μm area, 2s) to access the drug 
distribution on the samples. Drug release studies were carried out on the Faculty of Pharmacy, 
Universidade Nova, Lisbon. 
2.4.1 - Preparation of the samples 
During preparation of levofloxacin loaded cement pastes with biphasic powder (BTCP) 
using anhydrous sodium hydrogen phosphate as liquid phase composition, it was verified that 
resulting cement paste exhibited two phases (liquid and solid) instead of one (as per usual with 
the samples without levofloxacin). This phenomenon was attributed to the lower solubility of 
the levofloxacin in basic solutions when compared to acidic solutions. In order to verify this 
issue, the pH of the two used liquid phases (anhydrous hydrogen phosphate and citric acid) was 
measured and, as expected, the citric acid solution has a pH of 1.65, compared to the 8.58 pH 
value of the anhydrous sodium hydrogen phosphate solution. High pH values causes 
insolubility of levofloxacin and consequently, the hindrance of cement setting with subsequent 
phases separation. To overcome this problem, it was decided to use citric acid (10%) as liquid 
phase for BTCP levofloxacin loaded samples for release studies.  
Accordingly, cement samples were prepared using the formulations described in Table 
8. The resulting pastes were molded into cylinders (height: 12 mm; diameter: 6 mm), incubated 
for 24 h (37.5ºC, 80 % humidity), frozen for 2 days (-80ºC) and lyophilized. In order to assess 
the influence of the lyophilization on the drug release rate, samples from batch 2 (Table 8, 
TCP-0.30-L-OD and TCP-0.30-OD) were placed 4 days in a drying oven at 40ºC (Oven dried) 
instead of being frozen and lyophilized.  
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Table 8 - Batch formulations of the CPCs used. 
Precursor Powders 
(P) 
Liquid medium 
(L), 
Concentration 
(w/v %) 
L/P 
(mL g-1) 
Drying 
method 
Levofloxacin 
(w %) 
Cement  
Formulation Name 
β-TCP + MCPM Citric acid, 15 % 0.30 Lyophilisation 2.5 Batch 1 TCP-0.30-L-Lyof 
β-TCP + MCPM Citric acid, 15 % 0.30 Lyophilisation 0.0  TCP-0.30-Lyof 
β-TCP + MCPM Citric acid, 15% 0.30 Oven dried 2.5 Batch 2 TCP-0.30-L-OD 
β-TCP + MCPM Citric acid, 15% 0.30 Oven dried 0.0  TCP-0.30-OD 
β-TCP + MCPM Citric acid, 15 % 0.34 Lyophilisation 2.5 Batch 3 TCP-0.34-L-Lyof 
β-TCP + MCPM Citric acid, 15 % 0.34 Lyophilisation 0.0  TCP-0.34-Lyof 
BTCP Citric acid, 10 % 0.34 Lyophilisation 2.5 Batch 4 BTCP-0.34-L-Lyof 
BTCP Citric acid, 10 % 0.34 Lyophilisation 0.0  BTCP-0.34-Lyof 
 
2.4.2 - In vitro drug release assay 
Levofloxacin loaded cylindrical samples were tested in order to determine the drug 
release profile and kinetics. For this study, 3 levofloxacin loaded cylinders and one blank 
(without loaded drug) from each batch formulation were used, amounting to a total of 16 
samples. Samples were accurately weighted, placed on a 50 mL Falcon tube and immersed in 
25 mL of a biomimetic medium (phosphate buffer saline, PBS, Sigma-Aldrich) at pH 7.4. The 
tubes were then placed on a 37ºC water bath (Memmert, Germany) and shaken horizontally 
(130 rpm) during the assay (72 h) (Figure 14A).  
At pre-determined times of 10 min, 0.5h, 1h, 2h, 4h, 6h, 8h, 24h, 48h and 72h, 5 mL of 
each medium was collected (and replaced with the same volume of fresh medium) and analysed 
via UV-spectrometry, at 288 nm in a multiplate reader (FLUOstar Omega, BMG Labtech) in 
Chapter 2: Materials and Methods 
 
 
37 
 
triplicate, as shown in Figure 14B. The absorption of the medium collected from the 
correspondent blank samples at the same time points were used as controls. 
Calibration curves were prepared in PBS medium with 7 standards (i.e. 75, 65, 50, 40, 
25, 15 and 5 g mL-1 of levofloxacin). The absorbance of PBS was also measured to be used 
as blank. The calibration curves were repeated for each time point and 3 replicates were 
considered for each standard. The standards were prepared from a levofloxacin stock solution 
(with a concentration of 500 g mL-1, obtained by the dissolution of 125 mg into 25 mL PBS,) 
maintained at 37ºC during the assay. 
The main assessments made during the release study are as follows: 
i. Levofloxacin release profile (over a 72h period); 
ii. Release kinetics. 
Following the results of the antibiotic release essay, the best formulations were then 
used to fabricate the microneedles.  
A B 
Figure 14- Schematic representation of drug release studies procedure. Each sample is immersed in 
a PBS medium and placed on a 37ºC water bath (A). After a certain time point is reached, 200 µL 
aliquots from each sample (and blank) are transferred in triplicate (rep. 1 to 3) to a 96-well 
microplate and analyzed via UV-spectrometry at 288 nm (B). 
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2.5 – Stage 5: Microneedle fabrication 
The preparation of the cement pastes for the microneedles casting was conducted as 
described in section 2.3. The prepared pastes were then poured into a mold as seen in Figure 
15. Several casting processes were used to obtain the best filling results (filling full length of 
the needle):  
i. Manual casting: the pastes were poured into the mold and pressed downwards with a 
spatula; 
ii. Vacuum casting: the pastes were poured into the mold and placed in a vacuum 
chamber; 
iii. Ultrasound casting: after pouring the pastes into the mold, the mold was then placed 
into a Petri dish and sonicated. 
The manual filling was the technique that produced the best results and was the one used 
throughout this thesis. Mechanical properties and SEM imaging were used to characterize the 
samples, according to the procedure described in section 2.3.2 and 2.3.4, respectively. 
 
Figure 15- Silicon molds used to produce the microneedles. 
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3. Results and Discussion 
3.1 - Characterization of the starting powders  
As stated in Chapter 2, CaP based powders where synthesized via wet chemical 
precipitation method, where a close monitoring of the pH and temperature was made 
during the full complete synthesis time (180 min). These two parameters are of paramount 
importance since they influence the phases formed. pH evaluation with time for all nine 
synthesis is plotted in Figure 16, while average temperature measurements for each 
synthesis are presented in Figure 17.  
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Figure 17 - pH values throughout the duration of the reaction for synthesis I to IX. 
Figure 16 - Average temperature values for synthesis I to IX. 
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As seen in Figure 17, the temperature could not be maintained at a steady 30ºC 
being observed slight variations in the several syntheses evaluated (S I-IX). Concerning 
pH, higher variations are observed in the first hour attaining more stable values from this 
time to the end of the synthesis. Oppositely, synthesis S-VIII and S-IX presents the 
highest pH values almost stable (pH 8 - 8.5) throughout full synthesis time, resulting from 
the higher amount of ammonia added in the beginning of the synthesis.  
The dried powders resultant from the previous synthesis were then calcined (first 
calcination at 1000ºC/2h holding time). X-ray diffraction was used to identify crystalline 
phases of the powders in all the synthesis evaluated (S - I to IX). Figure 18 presents the 
results obtained. 
For the experimental conditions used (Ca/P = 1.51, pH 7-8 and 30 ºC) powders 
from S-II, III, VII, VIII and IX presented β-TCP as its main phase with different amounts 
of HA as secondary phase, except for powders resultant from S-I, IV, V and VI which 
seemed to be pure -TCP. The existence of HA in some powders could be explained by 
the fluctuations in pH and temperature observed during their synthesis (Figure 16 and 17, 
respectively), essentially in the first hour of the synthesis. None of the synthesized 
powders presented a detectable β-CPP phase being a good indication for going further 
with -TCP to -TCP transformation, since is stablished from a previous work that a β-
CPP phase produces an undesired effect in the → -TCP transformation [95, 127]. 
However, detecting low quantities of β-CPP phase by X-ray diffraction is not an easy 
task, as its most intense (2θ = 29.6 º) and second most intense (2θ = 27.6 º) peaks overlap 
the β-TCP peaks. Only the third most intense peak (2θ = 28.9º), not being overlapped by 
any other peak, is used to identify this phase. Oppositely, traces of HA phase are easier 
to identify, with its most intense peak (2θ =31,8 º) not overlapped by any of the β-TCP 
peaks.  
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Figure 18 - Diffractogram of the calcined powders resultant from synthesis I-IX. The 
standard JCDD PDF (codes in Table 5, section 2.2.2) of HA, TCP and CPP are also 
presented for comparison. 
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According to these results, powders from S-I, IV, V and VI were selected to 
proceed with further studies with -TCP powder. Powders from S- II, III, VII, VIII and 
IX were mixed and then submitted to the second calcination in order to obtain -TCP. 
Unfortunately, powders II and III were mislabeled for V and VI, by mistake. So, in reality, 
the following mixtures were obtained: S-I, II, III and IV for following with TCP studies 
and S-V, VI, VII, VIII and IX for going further for  to -TCP transformation (second 
calcination at 1250ºC/10h holding time). Figure 19 presents the XRD results of the 
resultant powder after the second calcination. 
  
Figure 19- Diffractogram of the powder resultant from the second calcination. 
The standard JCDD PDF (codes in Table 5, section 2.2.2) -TCP and TCP 
are also presented for comparison. 
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Surprisingly, as it can be seen, the obtained powder is not pure -TCP, but a 
mixture of -TCP and -TCP, so a biphasic powder. The quantification of these 
crystalline phases obtained by Rietveld refinement shows that powder presents 70 wt.% 
of α-TCP and 30 wt.% of β-TCP, which fitting is presented in Figure 20. This means that 
powder from synthesis V and/or VI after first calcination (Figure 18) should be 
Figure 20- Rietveld refinement used to access the amount of the crystalline 
phases in the powder resultant from second calcination. 
Figure 21 - FTIR spectra of powders resultant from synthesis V and VI (S-V 
and S-VI) after first thermal treatment. 
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responsible for the appearance of -TCP. To clarify this, FTIR has been evaluated in these 
both powders, which results are presented in Figure 21. 
In fact, powder resultant from synthesis V is not only -TCP as identified by X-
Ray diffraction (Figure 19) but present a small amount of -CPP, only detected by FTIR. 
The presence of the characteristic vibrational modes of the PO4 groups (around 550 cm-
1, 607 cm-1, 942 cm-1, 970 cm-1 and 1042 cm-1) confirm the β-TCP phase formation [139]. 
The marked bands at 727 cm-1 and 1212 cm-1 are characteristic of P2O74- group of β-CPP. 
These bands are clearly visible in the spectrum of S-V and not in S-VI, confirming the 
existence of traces of β-CPP in S-V, which stabilizes-TCP phase, explaining the 
existence of -TCP phase after the second thermal treatment in the full mixture [95, 127]. 
From this point forward, the raw powders will be referenced as follows: 
 TCP (for -TCP powder);  
 BTCP (for biphasic powder). 
PSD analysis was determined using the procedure described in Chapter 2, section 
2.2.1. Based on previous works [127], the milling was conducted in a controlled manner. 
The powders were milled and analyzed for PSD in timed intervals to avoid decreasing the 
D50 particle size below 1 μm. Figure 22 presents particle size distribution of TCP and 
BTCP powders.  
 
  
Mixture D10a D50b D90c Dmeand 
TCP 0.38 1.01 2.54 1.29 
BTCP 0.43 1.27 2.62 2.07 
aD10: 10% of the total particles are bellow this size; 
bD50: 50% of the total particles are bellow this size; 
cD90:90% of the total particles are bellow this size; 
dDmean: average particle size; 
 
Figure 22- Particle size distribution of the TCP and BTCP powders.  
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The particle size distribution is one of the most important powder characteristics 
for cement pastes preparation. Although the particle size distribution mentioned in the 
previous work (bimodal distribution with D50 around 1 m) was used to obtain injectable 
cement pastes [127], a similar PSD can be also used to prepare ceramic pastes for molding 
microneedles. Since the tip of the microneedles ranges form 25-100 μm ideally, reaching 
a D50 around 1-1.5 μm guarantees that this parameter will not influence the molding 
process. The D50 was used as reference parameter to choose when to stop the milling 
process.  
Both TCP and BTCP powders, present a similar bimodal particle size distribution 
with D50 around 1.01 μm and D50 around 1.27 μm, respectively. Bimodal particles size 
distributions are likely to allow the preparation of pastes with highly packing behavior, 
important factor to avoid high porosity levels and improve the mechanical properties of 
the final cements [140]. 
Chapter 3: Results and Discussion 
 
 
47 
 
3.2 - Characterization of the cement pastes 
Self-setting pastes for casting microneedles molds might follow two important 
criteria: (1) high initial setting time to allow paste preparation and complete casting and 
(2) adequate mechanical properties for complete de-molding and skin penetration without 
damaging. TCP and BTCP cement pastes were tested for its ISTs and FSTs to better 
understand how an optimization of the molding process could be made. Figure 23 shows 
the ISTs and FSTs of the cement pastes obtained from TCP and BTCP powders, according 
to the compositions presented in Table 6 and 7 (Chapter 2). 
Figure 23 - Initial setting time (IST) and Final setting time (FST) of the cement 
pastes obtained from TCP (A) and BTCP powders (B), according to the 
compositions presented in Table 6 and 7 (chapter 2). 
A 
B 
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For this analysis, the influence of L/P ratio, liquid composition and the addition 
of levofloxacin in IST and FST were studied for both powders. As expected, as L/P ratio 
increases, IST and FST increases for both powders [141]. For TCP, IST increases from 
around 2 min to 5 min when L/P changes from 0.28 to 0.34 while for BTCP, IST increases 
from 10 min to 20 min when L/P increases from 0.28 to 0.40. For a given L/P ratio, the 
presence of levofloxacin increases the IST and FST for all cement pastes tested, when 
compared with the same cements without levofloxacin. These results are in good 
agreement with results obtained by other authors [141,143]. 
Comparing the two liquid compositions used in BTCP cement pastes, for the same 
L/P ratio (0.34) is possible to observe that IST and FST increases from 14 min to 17 min 
for 10 % AC solution, but decreases to 6 min for 15% AC solution. Adding higher 
amounts of AC (from 10 to 15 wt %) in aqueous solution, IST and FST decreases. Since 
for 15 wt.%, IST is too low (5 min), it means that time for casting the paste in the mould 
will be short to guarantee flowing conditions of the paste to the deeper parts of the mould. 
Due to that, 10 wt.% of AC solution was used for further studies and the remaining 
compositions were discarded. 
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3.3 - Characterization of the CPCs 
3.3.1 - Mechanical strength, porosity and crystalline phases 
The as-prepared TCP and BTCP cement pastes were molded into cylinders and its 
mechanical properties tested following the methodology described in section 2.3.2. 
Compressive strength (A), porosity (B) and crystalline phases (C) of TCP (Figure 24) and 
BTCP (Figure 26) cement samples, in presence and in the absence of antibiotic, dried in 
different conditions, were tested. Figure 25 and Figure 27 present the XRD of the resultant 
cements from TCP and BTCP powders, respectively.  
Figure 24- Compressive strength (A) total porosity (B) and crystalline phases (C) of the 
TCP samples submitted to oven drying (TCP-0.28-OD, TCP-0.30-OD, TCP-0.34-OD) 
and lyophilization without levofloxacin (TCP-0.28-Liof, TCP-0.30-Liof and TCP-0.34-
Liof) and with levofloxacin (TCP-0.30-L-Liof, TCP-0.34-L-Liof). In figure C, a refers 
to oven dried, b to oven dried + 2.5 wt.% levofloxacin, c to lyophilized and d to 
lyophilized samples + 2.5 wt.% levofloxacin. 
B A 
C 
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Figure 25 - Diffractogram for TCP samples for oven drying (A), oven drying + 2.5% 
levofloxacin (B), lyophilization (C) and 2.5% levofloxacin + lyophilization (D). 
A B 
C 
D 
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As shown in previous works [127], the mechanical properties and the porosity of 
the CPCs are tightly related. As the porosity of a sample increases, its mechanical strength 
should decrease, and vice versa. Moreover, compressive strength of cements increases as 
L/P ratio decreases with concomitant decreasing of porosity. This trend was verified when 
L/P ratio changes from 0.30 to 0.34 mL.g-1, instead for 0.28 mL.g-1 (Figure 24A) when 
compared with higher L/P ratios. It can be attributed to: (i) higher viscosity of the pastes 
for 0.28 mL.g-1L/P ratio, which difficult the casting procedure with subsequent air 
bubbles trapped in the cement paste; (ii) DCP as crystalline phase formed, which presents 
lower density than brushite phase.    
As it can be seen, drying samples by lyophilization increased the overall 
compressive strength in all tested TCP samples when compared to the oven dried samples. 
These results are in good agreement with porosity data (Figure 24B), since a lower 
porosity increases the mechanical strength of the cement. For 0.30 mLg-1 L/P ratio, the 
addition of levofloxacin decreases the compressive strength of the cements (oven dried 
and lyophilized), with concomitant increase in porosity values, while for 0.34 mLg-1 L/P 
ratio, slightly variations in both properties were observed. This could be explained by the 
incomplete transformation of -TCP in brushite (DCPD) phase (Figure 24C and Figure 
25) for the TCP-0.34-liof in absence of levofloxacin. 
For cements obtained from BTCP powders, increasing L/P ratio resulted in an 
expected decrease in compressive strength for the cement samples prepared with aqueous 
solution containing 3 wt.% HP (Figure 26A The porosity results (Figure 26B) for the 
BTCP samples indicate that using sodium hydrogen phosphate instead of citric acid 
results in similar porosity values for the same L/P ratio (0.34). Increasing citric acid 
concentration from 10 to 15-wt% decreases compressive strength values with a 
simultaneous increase of porosity. Since citric acid acts like an accelerator of the setting 
reaction (Figure 23B), viscosity of the cement paste increases rapidly and consequently 
handling time decreases. Due to that, casting procedure is difficult (likely to air bubbles 
formation), particles arrangement becomes more difficult resulting in a highly porous 
structure.    
According to the results obtained for TCP cements, addition of levofloxacin 
slightly decreases compressive strength, as well as, increases porosity.  
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 The cement compositions were analyzed via XRD in order to identify the 
converted crystalline phases.  
Figure 26- Compressive strength (A), porosity (B) and crystalline phases (C) of the 
BTCP samples submitted to oven drying and lyophilization and with a fixed liquid 
phase of hydrogen phosphate and 10% and 15% citric concentration. 
A B 
C 
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For the BTCP samples (Figure 26C and Figure 27) prepared with HP liquid, 
CDHA is the main phase with unreacted α-TCP and β-TCP. In presence of AC as liquid 
phase, cements from BTCP powders present unreacted -TCP as the main phase with 
small amounts of brushite for BTCP-0.34-10AC in absence or in presence of 
levofloxacin. For cement prepared with 15-wt% citric acid, monetite (DCP) was formed 
instead of brushite. This can be attributed both to the lower setting times and pH values 
of the cement paste.  
The differences in the phases composition between BTCP cements prepared with 
HP and AC as liquid composition, explain the higher compressive strength values 
obtained for the cement samples prepared with HP. In fact, BTCP-0.34-HP3-OD and 
BTCP-0.34-AC10-Liof cement samples present similar porosity values while 
compressive strength of the first is around 34 MPa, significantly higher value than the 
second one (around 18 MPa). The higher compressive strength is related to the higher 
amount of CDHA (apatitic phase) in BTCP-0.34-HP3-OD. 
Figure 27- Diffractograms of the BTCP samples, for hydrogen phosphate (A) and 
citric acid (B). 
A 
B 
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Comparing brushitic (Figure 24) and apatitic cements (Figure 26), as for example 
TCP-0.34-Liof and BTCP-0.34-HP3-OD, similar porosity values can be observed while 
compressive strength is significantly higher for the apatitic one, as expected.      
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3.3.2 - Surface analysis  
The microstructural characteristics (surface) of the CPCs obtained from TCP 
powders, i. e., TCP-0.30-L-OD, TCP-0.30-OD, TCP-0.30-L-Liof, TCP-0.30-Liof, TCP-
0.34-L-Liof and TCP-0.34-Liof are presented in Figure 28. Figure 29 presents the 
micrographs of the BTCP-0.34-L-Liof and BTCP-0.34-Liof cements.  
 The large spherical pores shown in Figure 28 are most likely due to air bubbles 
trapped in the cement paste during mixing and molding. Analyzing surface 
microstructures of the TCP cements obtained from 0.30 mL.g-1 L/P ratio (Figure 28), 
oven dried and lyophilized, is possible to observe that lyophilized samples presented a 
smooth surface with apparently less porosity, in good agreement with compressive 
strength values for lyophilized samples (Figure 24A). Since total porosity values are 
similar for oven dried and lyophilized samples (Figure 24B), pore size and size 
distribution should be different, i.e., lyophilized samples should present small pores 
homogenously distributed, which could explain the better mechanical properties obtained 
for lyophilized TCP cements (Figure 24A). The presence of levofloxacin seems to 
decrease the crystals size, more visible in lyophilized TCP samples prepared with 0.34 
mL.g-1.  
For the BTCP samples (Figure 29), the presence of levofloxacin appears to 
increase porosity on the surface with larger pore size, in concordance with the results 
presented in Figure 26 A and B.   
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Figure 28 – Surface SEM images of the TCP samples (TCP-0.30-OD, TCP-
0.30-Liof, TCP-0.34-Liof) with and without levofloxacin. 
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Figure 29- Surface SEM images of the BTCP samples (BTCP-0.34-liof) with and without 
levofloxacin. 
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3.4 - Antibiotic release studies 
3.4.1 - Quantification method 
Calibration curves (and their respective equations) were calculated for each time 
point (see table in figure 30), and illustrated in Figure 30: Linearity (5-75 g mL-1) and 
reproducibility were analyzed and considered adequate for sample analysis, with a 
coefficient value (CV/%) of 0.005 > CV > 0.251. 
 
 
Clearly, as shown in Figure 30 by the decreasing slope, there was some 
degradation of the levofloxacin in the media over the 72h period. Comparing the curves 
with the highest concentration (75.00 g mL-1) between the 10 min and 48h time points, 
a decrease of 30.79 % over this period suggests that not only light, but also temperature, 
influence the stability of the levofloxacin in the solution and therefore, the levofloxacin 
released by the samples as well. Nevertheless, the effect of temperature is compensated 
as the concentration of the drug in the release media was calculated using the levofloxacin 
standard incubated during the same time frame.   
0.000
0.500
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3.000
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Figure 30 - Calibration curves for each time point and their respective equations and coefficient 
of determination (r2). 
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3.4.2 - In-vitro drug release  
Figure 31 presents release profiles of levofloxacin from the 4 batches studied 
(table 8, chapter 2, section 2.4.2).  As it can be seen, a complete levofloxacin release was 
achieved for TCP-0.30-L-Liof, TCP-0.30-L-OD and TCP-0.34-L-Liof after 48h and, for 
BTCP-0.34-L-Liof , after 24h (Figure 31B). The drying process had no influence over the 
levofloxacin release, as TCP-0.30-L-Liof and TCP-0.30-L-OD present similar 
cumulative percentage values at all time points (Fig.31 and Table 9). 
Between TCP-0.30-L-Liof and TCP-0.34-L-Liof, a faster release profile for TCP-
0.34-L-Liof indicates that L/P has some influence over the release rate. Levofloxacin 
release increased 9.6% in 24 h, from 75.0 ± 1.6% (TCP-0.30-L-Liof) to 84.6 ± 7.4% (TCP-
0.34-L-Liof). BTCP-0.34-L-Liof presents the fastest release profile, with 108.8 ± 6.9% of 
levofloxacin release over a 24h period. 
Table 9 - Cumulative % of levofloxacin released from formulations TCP-0.30-L-Liof (1) and 
TCP-0.30-L-OD (2). Mean ± SD (n=3). 
  
 
 
 10min 30min 1h 2h 4h 6h 8h 24h 48h 
1 4.6 ±0.3% 
8.2 ± 
0.2% 
13.6 ± 
0.1% 
19.8 ± 
0.6% 
30.3 ± 
0.7% 
37.4 ± 
1.4% 
49.9 ± 
0.8% 
75.0 ± 
1.6 % 
121.1 ± 
8.5% 
2 4.0 ± 0.2% 
7.9 ± 
0.6% 
12.7 ± 
0.9% 
18.9 ± 
2.4% 
29.5 ± 
1.5% 
37.1 ± 
3.7% 
49.7 ± 
2.6% 
74.5 ± 
6.1% 
122.5 ± 
7.5 % 
 
Figure 31- In vitro release profiles of the different cement formulations tested (A) and zoom 
of fig. 31 for the first 8h (B). Markers and error bars represent mean ± SD (n=3). A 
percentage above 100% is shown in the xx axis to better represent all the obtained data. 
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3.4.5 - Kinetics 
The release kinetic mechanism was obtained with the experimental release data 
fitted to different kinetic models including: First order; Higuchi and Coupled mechanism 
[144] (Table 9). For all the formulations, at least half of the levofloxacin content was 
released in the first 8 hours, even with some major differences between them. Using the 
Higuchi model for that period, we can observe that the α-TCP (BTCP-0.34-L-Liof) has a 
higher kH than the β-TCP formulations, indicating a higher initial release rate. Moreover, 
the good fit of release data to the Higuchi model (during the first 8h) suggests that the drug 
is released by simple diffusion mechanism within this initial time frame (Bettencourt et al., 
2000). Overall, the best fitting model for all samples was the designated “coupled 
mechanism”, first described by Frutos et al. [145] and previously used to describe other in 
vitro release studies of drugs from bone cements [146,147]. The model, defined in the third 
equation on Table 10, suggests a mechanism based on dissolution/diffusion process with an 
initial burst effect. The term b(1 – e-kcmt) is associated with a first order kinetic dissolution 
process and the term c√t with Fickian diffusion. The b and c parameters represent the 
contributions (in percentage values) of the dissolution and diffusion processes to the release 
of levofloxacin at any t time, and the parameter a is associated with the initial burst effect. 
The b and c parameters varied inversely, with the dissolution parameter (parameter b) 
prevailing over the diffusion (parameter c) process for all samples (Fig. 32), while the 
parameter a in BTCP-0.34-L-Liof suggests a stronger initial burst release over the other 
three formulations.  As so, on the first 8 hours, due to the higher concentration of 
levofloxacin in the samples vs. the medium, the diffusion process prevails. As the 
equilibrium is reached, the dissolution process controls the rate at which the levofloxacin 
is released within the 72 hours. 
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Table 10- Fitted parameter values and r2 for the different equation models used to determine the 
release kinetics of levofloxacin in CaPs TCP-0.30-L-OD (1), TCP-0.30-L-Liof (2), TCP-0.34-L-
Liof (3) and BTCP-0.34-L-Liof (4). 
Equation models Model parameters Formulations 
  1 2 3 4 
First order k1 (h-1) 0.001 0.001 0.002 0.003 
Lt = 1 - e-k1t r2 0.9982 0.9983 0.9982 0.9978 
Higuchi (8h) kH (h-1/2) 0.5089 0.5089 0.551 0.7239 
Lt = kH √t r2 0.9862 0.9845 0.9893 0.9978 
Coupled mechanism a 0.3087 0.2072 0 6.4022 
Lt = a + b (1 - e-kcmt) + c√t b 73.178 153.40 25.029 104.89 
 c (h -1) 1.784 1.722 1.804 0 
 r2 0.9982 0.9983 0.9982 0.9978 
Lt denotes fraction of levofloxacin released at a given time t. k1 and kH are constants of the mathematical models; a 
represents the burst effect, b is related with the dissolution process and c with the diffusion process of the “coupled 
mechanism” model.  
  
  
Figure 32 -Levofloxacin release fitted curves with the "coupled mechanism" with the 
parameter of the model equation presented.  
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3.5 - Evaluation of levofloxacin distribution throughout cement samples 
 Raman spectra of the microneedle plates was used to access the distribution 
of the levofloxacin in oven dried and lyophilized samples. Both sides of the array were 
analyzed. The bottom side refers to the side without microneedles while top side refers to 
the side of MN plate (containing the microneedles). Figure 33 presents the Raman spectra 
obtained in both sides of MN plates for a TCP based MN obtained with 0.34 mLg-1 L/P 
ratio, oven dried and lyophilized, as well as, BTCP based microneedle obtained with the 
same L/P ratio and dried in both conditions. As expected, all samples presents CaP bands 
visible at 970 cm-1 [139] and levofloxacin bands at 1395 cm-1, 1614 cm-1, 1726 cm-1[148, 
149]. Since this analysis is qualitative, it is only possible to extrapolate conclusions within 
the same sample, by comparing the CaP and levofloxacin intensity bands ratio (most 
intense ones). However, comparing the Raman spectra obtained in top and bottom sides 
of TCP-0.34-L-OD and TCP-0.34-L-Liof based MN is difficult to observe significant 
differences and to draw reliable conclusions.   
 In order to shed light on this point, Raman confocal images were also obtained 
in both sides of the MN plates, which are presented in Figure 34 and 35 for, TCP-0.34-L 
(OD and Liof) and BTCP-0.34-L (OD and Liof), respectively.   
 Looking to the TCP samples (Figure 34), it seems that the lyophilized samples 
benefit from this drying procedure, as the drug distribution seems to be more homogenous 
than in the oven dried samples. On the other hand, the results from the BTCP samples are 
quite ambiguous, being difficult to draw any firm conclusions concerning the influence 
of drying process on drug distribution.  For that, additional experiments should be 
evaluated.  
 Furthermore, since drug release profiles for oven dried and lyophilized 
samples have been similar (Figure 31), it means that levofloxacin distribution throughout 
cement samples should be analogous in both drying procedures. 
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Bottom 
Bottom 
Top 
Top 
Figure 33 - Raman spectra of the microneedles from both sides of the array, top side (right, 
with needles) and bottom side (left, without needles). 
Figure 34- Combined Raman images of TCP-0.34-L-OD (first row) and TCP-0.34-L-
Liof (bottom row) samples. Blue corresponds to CaPs and the red to Levofloxacin. 
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Bottom 
Bottom 
Top 
Top 
Figure 35 - Combined Raman images of BTCP-0.34-L-OD (first row) 
and BTCP-0.34-L-Liof (bottom row) samples. Blue corresponds to CaPs 
and the red to Levofloxacin on the first row, but on the bottom blue is 
CaP and red is levofloxacin. 
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3.5 Microneedle characterization 
3.5.1 - Mechanical properties and SEM imaging 
To have a better perspective of the microneedle array, images of the microneedles 
were taken using a regular camera (13 MP), a magnifying glass camera (Leica EZ4 HD) 
and a SEM microscope. SEM imaging (x30, x100 magnifications) was used to 
characterize microneedles and to measure them, while the other camera was used to 
acquire images that better represent the arrays. The results are shown in Figures 36-38. 
Figure 36- TCP-0.30-L-Liof microneedles. Images taken with camera (top left) a magnifying glass 
camera (top right) and SEM (bottom) with x30 and x100 magnifications. 
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Figure 38 - BTCP-0.34-L-Liof microneedles. Images taken with camera (top left) a 
magnifying glass camera (top right) and SEM (bottom) with x30 and x100 magnification. 
Figure 37 – TCP-0.34-L-Liof microneedles. Images taken with camera (top left) a magnifying 
glass camera (top right) and SEM (bottom) with x30 and x100 magnifications. 
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All the above images show fully filled needle tips and some partially filled. The 
incomplete filling is derived to the not-yet optimized molding procedure and the PSD not 
being optimal (> 1 µm), as the larger particles can obstruct deeper parts of the mold (tip 
of MN). Other mentioned techniques (chapter 2, section 2.5), such as vacuum filling, had 
slightly worse filling performance for the same needle geometry [141], confirming the 
manual filling as the best molding method for high viscosity pastes.  
The tips of the TCP-0.30-L-Liof, TCP-0.34-L-Liof and BTCP-0.30-Liof and 
BTCP-0.34-L-Liof based microneedles were tested by compressive test to evaluate the 
maximum force that can be applied to the MN without damaging the tip. Results are 
presented in Figure 39. These values should be prudently analyzed since the MN in the 
array could present different length resultant to the incomplete fill of the MN mold (high 
standard deviation values). As higher the length of MN, as sharper is the tip resulting in 
smaller tip surface area and, consequently, lower mechanical resistance. The TCP-0.34-
L-Liof composition was the most resistant with 110 N, followed by the TCP-0-30-L-Liof  
with 77 N and the BTCP-0.34-L-Liof with 57 N. 
Comparing these results with the ones obtained by Cai et al. [16], the height of 
the fabricated needles is 4 times the size of the ones obtained in this study. 
  
Figure 39- Compressive force of the microneedles.  
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4. Conclusions and Future work 
With a main objective of producing drug-loaded ceramic microneedles capable of 
piercing the skin and successfully deliver all of the drug, this thesis can be considered a 
success, at least on that point. From the obtained results, we can conclude: 
 The control of pH and temperature of the synthesis reaction are essential 
experimental parameters to obtained the desired crystalline phases in CaP based 
powders; 
 The presence of Na2HPO4 in liquid phase composition used for the BTCP cements 
preparation avoids the solubilization of levofloxacin, interfering in the cement 
setting. 
 The L/P ratio influences the mechanical resistances of the cements; 
 The addition of levofloxacin increased the setting times of all the tested 
compositions; 
 The addition of levofloxacin slightly decreased the mechanical properties of the 
cements; 
 Drying process by Lyophilization increases the mechanical properties of the 
resultant cements; 
 All the cement based MN tested have enough mechanical strength to pierce the 
surface of the skin; 
 From the release assay, we can conclude that the levofloxacin is 100% released 
within the first 48 hours, for all compositions tested. 
As the microneedles present promising characteristics for future biomedical 
applications, further work should be done: 
 Developing an improved method for casting the microneedles; 
 Evaluate skin penetration tests with the self-setting microneedles obtained  
 Evaluate the transdermal drug delivery in situ. 
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